Pfizer (NYSE: PFE) recently received a number of ratings updates from brokerages and research firms:

  • 12/6/2017 – Pfizer was given a new $40.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 12/6/2017 – Pfizer was given a new $38.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 11/25/2017 – Pfizer was given a new $39.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 11/23/2017 – Pfizer was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $38.82 price target on the stock.
  • 11/16/2017 – Pfizer was given a new $39.00 price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.
  • 11/10/2017 – Pfizer had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $39.00 price target on the stock.
  • 11/1/2017 – Pfizer was given a new $39.00 price target on by analysts at J P Morgan Chase & Co. They now have a “buy” rating on the stock.
  • 11/1/2017 – Pfizer was given a new $39.00 price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.
  • 11/1/2017 – Pfizer was given a new $36.00 price target on by analysts at Goldman Sachs Group Inc. They now have a “neutral” rating on the stock.
  • 11/1/2017 – Pfizer was given a new $38.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 10/31/2017 – Pfizer was given a new $36.00 price target on by analysts at Berenberg Bank. They now have a “neutral” rating on the stock.
  • 10/31/2017 – Pfizer was given a new $39.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/26/2017 – Pfizer was given a new $39.00 price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.
  • 10/19/2017 – Pfizer had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $39.00 price target on the stock, up previously from $37.00.
  • 10/16/2017 – Pfizer was given a new $38.00 price target on by analysts at Jefferies Group LLC. They now have a “neutral” rating on the stock.
  • 10/11/2017 – Pfizer was given a new $38.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 10/11/2017 – Pfizer was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Pfizer is facing headwinds in the form of genericization of key drugs, lost alliance revenues, pricing pressure and rising competition which is hurting the top-line. Though Pfizer’s growing immuno-oncology portfolio offers strong potential, many of these assets are in early stage of development. Additionally, Pfizer’s shares have underperformed the industry this year so far. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals over the next five years, including around 15 products that have blockbuster potential. Bavencio is being considered a key long-term growth driver for Pfizer. The company has a mixed record of earnings surprises in recent quarters. Estimates have remained stable ahead of its Q3 earnings results.”
  • 10/11/2017 – Pfizer was given a new $38.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 10/10/2017 – Pfizer was given a new $37.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.

Pfizer Inc. (NYSE:PFE) traded down $0.07 during trading on Thursday, reaching $35.56. The company’s stock had a trading volume of 17,379,200 shares, compared to its average volume of 19,978,311. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer Inc. has a 52 week low of $30.51 and a 52 week high of $36.78. The stock has a market capitalization of $212,380.00, a PE ratio of 14.25, a PEG ratio of 2.51 and a beta of 1.01.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period last year, the business posted $0.61 earnings per share. The company’s revenue for the quarter was up .9% compared to the same quarter last year. equities research analysts predict that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.60%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 60,280 shares of company stock valued at $2,118,988. Company insiders own 0.06% of the company’s stock.

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc and related companies with MarketBeat.com's FREE daily email newsletter.